Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th